Insurance Coverage

Stepwise guidance for deep and nonpalpable implant removal, the PCOS to PMOS renaming, IUD bleeding patterns in the first 90 days, OCP use and lower-extremity injury risk in athletes, cancer risk data for BRCA1/BRCA2 carriers on hormonal contraception

A store-brand version of Opill is now on shelves at Walgreens and CVS. Here's what providers need to know about this additional over-the-counter contraceptive option.

BV and STI co-infection, iron deficiency anemia trends, ACOG HIV and PrEP guidance, estetrol/drospirenone safety data

Patient decision-making around LARC extended use, contraceptive progestogens and meningioma risk, adolescent contraceptive decision-making, residual LNG in the 52mg IUD beyond 8 years

New research on Nexplanon bleeding patterns, contraceptive decision aid quality, TikTok and tubal ligation, post-Dobbs abortion safety beliefs, gender-affirming care gaps, and more.

PCOS renamed polyendocrine metabolic ovarian syndrome, updated ACOG cervical cancer screening guidelines, doxy-PEP losing effectiveness against gonorrhea

Stroke risk with CHC and triptan co-use, IUD self-removal patient perspectives and simulation, LMP dating accuracy in adolescents, intravaginal vitamin C for recurrent BV, sexual health concerns and contraceptive discontinuation, letrozole-misoprostol as mifepristone alternative, OB-GYN job satisfaction post-Dobbs

COCs vs POPs for heavy menstrual bleeding, five-year Miudella copper IUD data, VTE risk with body-identical estrogen COCs, OTC Opill self-screening, mood symptoms and progestin-only discontinuation, Dobbs and residency application trends